HIV / AIDS in the News

Shelby County sees surge in HIV cases, health officials seek solutions - WREG.com

 

Shelby County sees surge in HIV cases, health officials seek solutions - Yahoo

 

FDA Approves 1-Minute HIV Self-Test - Pharmacy Times

 

Atlanta: The Heartbeat and History of an Epidemic Still Fighting to Be Won - POZ - Health, Life and HIV

 

Project unearths voices from one of the world's first HIV/AIDS service organizations - Medical Xpress

 

OP-ED – A Letter to Julie McKnight: On Legacy, Love, and the Fight Against HIV - GLAAD

 

MK-8527 HIV PrEP monthly pills - Specialty Pharmacy Continuum

 

MK-8527 HIV PrEP monthly pills - Specialty Pharmacy Continuum

 

Gilead to present data on potential first weekly oral treatment for HIV - Clinical Trials Arena

 

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Benzinga

 

Gilead highlights HIV pipeline at European AIDS Conference - The Pharma Letter

 

Local leaders unite to address HIV awareness on National Latinx AIDS Awareness Day - WCIV

 

Switching to Merck’s DOR/ISL in HIV had 'minimal impact on weight and body composition - The Pharma Letter

 

A reader asked the Ethicist: I'm an HIV-positive gay man who protests regularly. My liberal friend, married to a Trump supporter, shares my fears about the U.S. but avoids protests; she only shares her views online. Her apathy feels hypocritical. Should…

 

Remembering HIV/AIDS in the illness's awareness month - Yahoo News UK

 

Pharmacy Owners Plead Guilty in Medicaid Fraud Involving Unregulated HIV Medications - HMP Global Learning Network

 

Immunotherapy approach offers hope for long-term HIV control without daily medication - Medical Xpress

 

Considering the effects of pair formation dynamics on mpox and HIV co-infection in the gbMSM community - Nature

 

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial - Seeking Alpha

 

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention - BioSpace

 

ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir - GSK

 

Retrospective event to honor AIDS Walk in place of the annual walk-a-thon - Philadelphia Gay News

 

ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir - Business Wire

 

Merck reports minimal weight changes in HIV treatment switch trials - Investing.com

 

Evaluating the impact of the COVID-19 pandemic on viral load and CD4 monitoring for people living with HIV on ART in rural Lesotho - BMC Infectious Diseases

 

Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study - Nature

 

Unraveling the impact of indoor air pollution on respiratory health in people living with HIV within a high-prevalence HIV cohort - BMC Pulmonary Medicine

 

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference - GuruFocus

 

In vitro comparison of the susceptibilities of the same drug resistance mutations to reverse-transcriptase inhibitors of subtype B and CRF01_AE HIV-1 strains - Nature

 

Gilead presents new HIV research data at European AIDS Conference - StreetInsider